FIND AN INFUSION SERVICE PROVIDER IN YOUR AREA.
You are about to leave the VYEPTI website for healthcare professionals
VYEPTI Dosing and Administration Video Coming Soon
By leaving this page, all selections will be lost. Do you want to continue?
About VYEPTI CONNECT
VYEPTI CONNECT offers eligible patients access support throughout their treatment with VYEPTI. Providers can enroll their patients so they may take advantage of the program's helpful offerings.
You can enroll your patients in VYEPTI CONNECT by:
Faxing an enrollment form to
866-868-7071
Calling 833-4-VYEPTI,
option 1
Mailing an enrollment form to:
2250 Perimeter Park, Suite 300
Morrisville, NC 27560
The VYEPTI CONNECT team is here to answer your access and reimbursement questions
Access and reimbursement support is provided by a team of reimbursement specialists.
VYEPTI CONNECT Liaisons
When you enroll your patients in VYEPTI CONNECT, you have access to a liaison who can assist with any of the VYEPTI CONNECT informational offerings.* Liaisons can be contacted by phone at 833-4-VYEPTI, option 1, Monday through Friday, 8 am-8 pm (ET).
Field Reimbursement Specialists
Access questions can also be directed to a Field Reimbursement Specialist (FRS) who can help in person, virtually, or by phone.
VYEPTI Permanent J-code (J3032)
The Centers for Medicare and Medicaid Services (CMS) Healthcare Common Procedure Coding System (HCPCS) has assigned VYEPTI® (eptinezumab-jjmr) a permanent HCPCS J-code: J3032. Learn more here.
Providing VYEPTI patients with access support
*VYEPTI CONNECT is only available for patients who have been prescribed VYEPTI and are enrolled in VYEPTI CONNECT; support may vary based on patient eligibility. Click here for full Terms and Conditions for VYEPTI CONNECT.
Benefits investigation
Benefits investigation informational support includes gathering medical coverage requirements, assignment of benefits, and, if applicable, infusion location requirements of the payer for VYEPTI.
Prior authorization (PA)/medical exception
PA/medical exception support provides information on the payer’s process for determining VYEPTI coverage, including blank PA forms that can be submitted to request patient access to VYEPTI. Once a PA is submitted, VYEPTI CONNECT can confirm the patient’s final coverage information for VYEPTI.
Appeals support
Appeals support offers information on the payer’s process if an HCP wants to appeal a denial or other decision regarding VYEPTI coverage. If an appeal is submitted, VYEPTI CONNECT can confirm the patient’s final coverage information for VYEPTI.
Infusion locations
Infusion locations can be provided by VYEPTI CONNECT for patients who need to infuse at a location other than their prescriber’s office or clinic. VYEPTI CONNECT can check the patient's insurance to confirm that the infusion locations are in their network. You can search directly for alternate infusion sites in your area here.
Prescription coordination
For offices that do not administer VYEPTI, VYEPTI CONNECT can send the VYEPTI prescription to an infusion location or in-network specialty pharmacy.
Infusion reminders
Infusion reminders can alert healthcare providers about their eligible patients’ upcoming VYEPTI infusions.
Your patients may pay as little as $0 for their VYEPTI infusion†
- Offer includes up to $200 in administration fees per VYEPTI treatment
- Includes 100 mg and up to 300 mg doses
- Applies to eligible commercial patients only
Patients can check eligibility requirements and enroll in the program by calling 833-4-VYEPTI, option 1, or learn more here.
Nursing support
Ongoing support from registered nurses is available for patients through VYEPTI GO. This support program provides information to patients on preparing for their infusions, answers questions about VYEPTI and migraine, and can direct them to helpful resources. Patients can learn more and enroll in the program by calling 833-4-VYEPTI, option 2, or learn more here.
Access and support resources
Enrollment form, sample letters of medical necessity and appeal, a PA checklist, VYEPTI CONNECT Copay Assistance Program information, and more tools and downloads are at your fingertips.
†Your patient’s out-of-pocket cost may vary depending on their dose, insurance coverage, and eligibility. Eligibility criteria and program maximums apply. This offer is NOT available for patients enrolled in Medicare, Medicaid, or any other government healthcare program. Please see the full Terms and Conditions.
IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.
INDICATION
VYEPTI is indicated for the preventive treatment of migraine in adults.
Warnings and Precautions
Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.
Adverse Reactions
The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.
For more information, please see the Full Prescribing Information and Patient Information.
IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.
INDICATION
VYEPTI is indicated for the preventive treatment of migraine in adults.
Warnings and Precautions
Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.
Adverse Reactions
The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.
For more information, please see the Full Prescribing Information and Patient Information.
© 2023 Lundbeck. All rights reserved. VYEPTI and VYEPTI GO are registered trademarks, and VYEPTI CONNECT and Migraine Victors Program are trademarks of Lundbeck Seattle BioPharmaceuticals, Inc. EPT-B-100032v14
This website is intended for US healthcare professionals only.
